Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration

Study Overview
=================
Brief Summary
-----------------
Anti-VEGF intravitreal injections are the treatment of choice in age-related macular degeneration (AMD). However 37% of patients are unresponsive or poorly responsive to these therapies. It is still not possible to foresee the patient's response to anti-VEGF injections. A poor response may be related to an activation of alternative pro-angiogenic pathways with over expression of many other pro-angiogenic cytokines. The primary goal of this study is to measure the aqueous humor concentration of pro-angiogenic cytokines in AMD patients.

Official Title
-----------------
Assay of Pro-angiogenic Cytokines in Exudative Age-Related Macular Degeneration

Conditions
-----------------
Age Related Macular Degeneration

Intervention / Treatment
-----------------
* Procedure: Aqueous humor samples collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Diagnosis of exudative age-related macular degeneration requiring intravitreal anti-VEGF treatment. Patient for whom the last intravitreal injection of anti-VEGF in the eye is strictly more than 3 months Signature of informed consent Affiliation to the French social security system Exclusion Criteria: Pregnant or nursing patient (a urinary pregnancy test will be performed) Systemic treatment with anti-VEGF Intravitreal treatment with anti-VEGF for less than 3 months regardless of the treated eye. Retinal pathology that can modify the secretion of pro-inflammatory cytokines such as diabetic retinopathy, venous occlusions, intermediate and posterior uveitis. Diabetes Mellitus High Myopia Simultaneous participation in another clinical research protocol in exudative AMD Person under guardianship, under curatorship, deprived of liberty

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Patients with exudative AMD<br> | Procedure: Aqueous humor samples collection<br>* In addition to the routine examinations performed as part of the usual care of AMD patients, an anterior chamber puncture will be performed to collect the aqueous humor samples.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of pro-angiogenic cytokines concentration in the aqueous humor of patients with exudative AMD at 3 months |  | At Month 3 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dose of VEGF in the aqueous humor of patients with exudative AMD |  | At Day 0, Month 1, Month 2, Month 3 | 
| Dose of pro inflammatory cytokines in the aqueous humor of patients with exudative AMD |  | At Day 0, Month 1, Month 2, Month 3 | 
| Measurement of visual acuity with Snellen chart |  | At Day 0, Month 1, Month 2, Month 3 | 
| Measurement of visual acuity with ETDRS visual acuity chart |  | At Day 0, Month 1, Month 2, Month 3 |